REPRINTED WITH PERMISSION OF IASP – Pain assessment in advanced dementia. Validity of the German PAINAD – a prospective double-blind randomised placebo-controlled trial

Journal Title: BÓL - Year 2018, Vol 19, Issue 4

Abstract

Pain in combination with dementia is a common condition that makes pain recognition significantly more difficult. This results in undertreatment of pain in those suffering from dementia. The Pain Assessment in Advanced Dementia (PAINAD) scale currently represents one of the best approaches to pain detection in dementia. In a pilot study, strong inter-rater and retest reliability of the German version (PAINAD-G) was proven. However, the available data concerning the validity of this instrument were insufficient. The aim of the study was to validate the PAINAD-G scale by a double-blind randomised placebo-controlled trial in people with advanced dementia expected to be in pain. A second aim was to examine whether other observational tools (BISAD5 Observation Instrument for Assessing Pain in the Elderly with Dementia) (German: Beobachtungsintrument fur das Schmerzassessment bei alten Menschen mit Demenz, Checklist of Nonverbal Pain Indicators, Algoplus) were also able to demonstrate a significant difference between the study groups. Surprisingly, the study revealed no difference in „pain reduction” between those treated by oxycodone compared with those treated by placebo. Equally, none of the other 3 observational tools were able to demonstrate a significant difference between the study groups. However, correlations among the 4 observational tools were mostly moderate to high. A number of possible reasons for this observation, such as difficulties regarding sensitivity to change/responsiveness, consistence of the fundamental construct, influence of the early onset study, and efficacy of the analgesic in advanced dementia are discussed.<br/><br/>

Authors and Affiliations

Albert Lukas, Ulrich Hagg-Grün, Benjamin Mayer, Thomas Flscher, Matthias Schuler

Keywords

Related Articles

Farmakoterapia bólu u pacjenta leczonego lekami psychotropowymi – dlaczego należy zachować ostrożność?

Farmakoterapia bólu u pacjenta, który równocześnie leczony jest z powodu chorób psychicznych jest znacznym wyzwaniem terapeutycznym. Zarówno wpływ analgetyków, szczególnie opioidowych, na stan psychiczny pacjenta oraz wp...

PRZEDRUK POLSKIEGO TŁUMACZENIA ARTYKUŁU ZA ZGODĄ INTERNATIONAL ASSOCIATION FOR THE STUDY OF PAIN (IASP) - Pain 156 (2015) 366-370 Rola macierzy zewnątrzkomórkowej w bólu przewlekłym w następstwie uszkodzenia

W bieżącym artykule dokonujemy przeglądu danych naukowych na temat roli macierzy zewnątrzkomórkowej w zwią- zanej z bólem plastyczności w obwodowym i ośrodkowym układzie nerwowym, plastyczności, która może ułatwiać przej...

Uśmierzanie bólu po urazie na etapie przedszpitalnym – wyniki wstępne

W ostatnim okresie nastąpiły znaczne zmiany w systemie Państwowego Ratownictwa Medycznego (PRM). Zmiany, między innymi, dotyczyły rozszerzenia wachlarza uprawnień ratowników medycznych. Od dawna poruszano w dyskusjach pr...

The role of interleukin-1 family of cytokines in nociceptive transmission

IL-1 family of cytokines, is a group of several proteins which are involved in regulation of immuneresponse. It has been shown that members of that family , especially: IL-1α, IL -1β, IL-18 and IL-33 act asmediators in n...

Download PDF file
  • EP ID EP609350
  • DOI 10.5604/01.3001.0013.2997
  • Views 60
  • Downloads 0

How To Cite

Albert Lukas, Ulrich Hagg-Grün, Benjamin Mayer, Thomas Flscher, Matthias Schuler (2018). REPRINTED WITH PERMISSION OF IASP – Pain assessment in advanced dementia. Validity of the German PAINAD – a prospective double-blind randomised placebo-controlled trial. BÓL, 19(4), 34-49. https://europub.co.uk/articles/-A-609350